Posted on 03/27/2021 7:02:37 PM PDT by nickcarraway
Dual-listed medicinal cannabis player, MGC Pharmaceuticals has received ethics committee approval from two Israeli hospitals for a Phase III clinical trial of its trademarked “CimetrA” anti-inflammatory treatment on patients diagnosed with COVID-19. The clinical trial will focus on the treatment of a large group of moderately sick, hospitalised COVID-19 patients.
The ASX and LSE-listed medicinal cannabis player received the green light for the trial from the Rambam Health Care Campus, Haifa and the Nazareth Hospital EMMS, both in Israel, where MGC Pharma previously saw success in the treatment of COVID-19 patients during a Phase II clinical trial.
The company expects the Phase III trial to commence in early April with interim results due out as early as June. Final results are expected to be tabled around October this year. MGC is looking for up to 252 trial patients across clinical test sites in Israel and Brazil as it seeks to have CimetrA registered as a drug.
The company said the recent name change from the original product name, ArtemiC, to CimetrA recognises the transfer of the product under the Phase III clinical trial to a heightened status as an Investigational Medicinal Product, or “IMP” status. The ArtemiC name will be retained for the formulation under the original ‘food supplement’ status.
The company said the CimetrA product encapsulates Graft Polymer’s proprietary self-nano emulsifying drug delivery system to deliver the active ingredients more effectively and in higher concentrations to the targeted cells.
CimetrA is a natural anti-inflammatory formulation based on Curcumin and Boswellia Serrata as anti-inflammatory agents with the supporting ingredient, Artemisinin, an antiseptic peroxide bridge. According to MGC Pharma, all the ingredients of CimetrA are well known, natural active ingredients with immunomodulatory properties.
MGC Pharma said it is fully funded to complete the trial after raising £6.5m for its successful IPO and listing on the London Stock Exchange. Furthermore, the company said it was ready to start production of CimetrA at its existing, Europe-based facilities with all permits and approvals already in place.
This is a very significant milestone for the Company, being the first Phase III clinical trial of CimetrA™. ArtemiC™ has already proven to be a very successful product for the Company, and we look forward to replicating this with CimetrA™ as an IMP and improve outcomes for COVID-19 patients.
MGC Pharma Managing Director and Co-founder, Roby Zomer Whilst the rest of the world is searching for the proverbial magic wand to strike down the retched Coronavirus, by cure or vaccine, MGC Pharma is quietly flying under the radar developing its treatment regimes, as more of a silver blanket than a silver bullet, to reduce the symptoms and thereby reduce the risk of death from the scourge.
NB: This article is for general financial markets news purposes only and is not to be taken as an endorsement of, or advertisement for any individual product, medicine or drug.
Good. Anything to get it down from the terrifying 0.25%!
MGC Pharma is quietly flying under the radar developing its treatment regimes, as more of a silver blanket than a silver bullet, to reduce the symptoms and thereby reduce the risk of death from the scourge.
Treatment regimes.
Wow....what a novel idea. A treatment, eh?
:-)
New anti-inflammatory on the Market might be good for other diseases also. Hope it turns out to be safe!
Can you imagine how many different kinds of actual treatments we could have now if the medical community pursued those options with the fervor and dedication they have displayed pushing the vaccines?
Patients reported a marked increase in hunger but were too mellow to care...
Ours lies the over all death rate for all ages and sexes is 1.8% and goes up significantly for the 65+ cohort into the double digits by the 70s
All the data up to date till this week is here, they even break out pneumonia and influenza deaths with and without covid so there is a point of data for those who died with covid and influenza positives
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm
Stick to real data not a number pulled out of someone’s backsides.
How about Johns Hopkins University school of medicine the world’s foremost authority on infectious diseases and mortality yeah I’ll take their word over internet blowhards here up to date data.
https://coronavirus.jhu.edu/data/mortality
Marketing 50.5. Reversing the spelling of the name of the product cause it hit a higher level of inquiry? Great way to keep name recognition. The whole info packet reads like this: “hey people, we have great product, you got spare money to waste?” They supposedly got ethics clearance. Got no patients yet...”self-nano...”...cool buzzword....”the wretched corona”...hey boys don’t sound too analytic...all the earmarks of a marketing scheme
Gee, thanks for fact checking my jokes. Someone's got to waste their time doing it.
Good. Anything to get it down from the terrifying 1.8%!
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.